Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

Hookipa Biotech AG. (4/22/14). "Press Release: Hookipa to Present at the Bio Equity Europe 2014". Vienna.

Region Region Amsterdam
  Country Netherlands
Organisations Organisation Hookipa Biotech AG
  Organisation 2 EBD Group AG (CH)
  Today EBD Group GmbH (DE)
  Group Informa Group (Group)
Products Product BioEquity Europe 2014 Amsterdam
  Product 2 Vaxwave® technology
Index term Index term Hookipa Biotech–Informa: investor conference, 201405 supply service Hookipa presents at BioEquity Europe 2014 in Amsterdam
Person Person Cohen, Katherine (Hookipa Biotech 2011–201606 CEO + Founder before Intercell)
     


Hookipa Biotech AG, today announced that the company's Chief Executive Officer, Dr. Katherine Cohen, will provide an overview of the company’s technologies and programs at the BIO Equity Europe 2014 (Amsterdam, The Netherlands, May 21-22; presentation on Wednesday, May 21, at 5:00 p.m. CET).


About Hookipa Biotech

Hookipa Biotech AG is developing a new class of innovative prophylactic and therapeutic vaccines based on its proprietary Vaxwave® technology. The Vaxwave® technology is a novel vaccine platform using a replication-defective viral vector for the prevention and treatment of multiple infectious diseases and cancer. The platform is one of the most promising new technologies for next generation vaccines due to its ability to stimulate both potent B-cell and CD8+ T-cell immune responses. Vaxwave® has been validated in various disease models. Unlike other vectors, Vaxwave® vaccines can be administered repeatedly to boost the immune system. The Company is focused on the development of its lead vaccine candidate HB101, a vaccine for immunization against cytomegalovirus (CMV) and plans to further industrialize the Vaxwave® technology and build a robust product pipeline in the area of infectious diseases and cancer. Hookipa has raised a total of EUR 27 million in equity finance from internationally renowned venture capital investors including Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners.


Contact:

Dr. Katherine Cohen
Chief Executive Officer
Hookipa Biotech AG
Helmut-Qualtinger-Gasse 2
1030 Vienna
Austria
Email: office@hookipabiotech.com

   
Record changed: 2017-07-02

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px

More documents for Hookipa Biotech AG


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px